Medical Technology

@xconomy.com 3 years ago

Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More

@xconomy.com 3 years ago

Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More

@xconomy.com 3 years ago

Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More

@xconomy.com 3 years ago

Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More

@xconomy.com 3 years ago

CereVasc Lands $44M for New Medical Device to Drain “Water on the Brain”

@xconomy.com 3 years ago

Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs

@xconomy.com 4 years ago

Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More

@xconomy.com 4 years ago

Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More

@xconomy.com 4 years ago

Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More

@xconomy.com 4 years ago

Novome Lands $33M to Tweak a Gut Microbe Into a Metabolic Therapy

@xconomy.com 4 years ago

Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More

@xconomy.com 4 years ago

Five Years After Y Combinator First Admits Biotechs, They’re Dug In

@xconomy.com 4 years ago

Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More

@xconomy.com 4 years ago

Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further

@xconomy.com 4 years ago

SpringWorks and Satsuma Boost This Week’s Biotech IPO Haul to $595M